SAN DIEGO, CA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage company focused on creating therapeutic solutions to address unmet needs in global health, today announced that a provisional patent application entitled: “SYSTEM AND METHODS TO ENHANCE CHEMOTHERAPY DELIVERY AND REDUCE TOXICITY” has been filed with the United States Patent and Trademark Office (“USPTO”).
Cancer is the second leading cause of death in the United States1. Despite therapeutic advances, treatment toxicity, drug resistance and inadequate tumor site delivery restrict the benefit of chemotherapeutic agents administered to cancer patients. More specifically, less than 5% of systemically administered chemotherapeutic agents are reported to reach their target tumor site2,3. Off-target chemotherapeutic agents contribute to treatment toxicity2,3 and may promote the spread of cancer metastasis4,5,6,7,8.
To overcome these challenges, Sigyn’s patent submission describes a therapeutic device system whose primary objective is to enhance chemotherapy delivery and reduce its toxicity. A secondary objective of the therapeutic system is to reduce treatment dosing without sacrificing patient benefit, or conversely increase chemotherapy dosing without added toxicity. In concert with these objectives, the therapeutic system offers to reduce drug resistance and inhibit the potential spread of cancer metastasis induced by the administration of chemotherapeutic agents.
“This patent submission is dedicated to friends and family members whose lives were taken by cancer,” stated Jim Joyce, CEO of Sigyn Therapeutics and the inventor underlying the patent submission. “Additionally, as we advance Sigyn TherapyTM to address life-threatening conditions that are beyond the reach of drugs, I want to clarify that the intent of this patent submission is to protect the development of a therapeutic system to improve the benefit of chemotherapeutic drugs already approved to treat cancer,” concluded Joyce.
On September 14, 2022, the Company announced plans to initiate first-in-human studies of Sigyn Therapy in End-Stage Renal Disease (ESRD) patients suffering from excess inflammation and/or endotoxemia. Sigyn Therapy is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies. Candidate treatment indications for Sigyn Therapy also include sepsis, community acquired pneumonia and emerging pandemic threats.
Sigyn Therapeutics is a development-stage company focused on creating therapeutic solutions to address unmet needs in global health. Sigyn Therapy™, the Company’s lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies.
Candidate treatment indications for Sigyn Therapy include sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), emerging pandemic threats, and inflammation & endotoxemia in end-stage renal disease patients.
The Company’s development pipeline includes a cancer treatment system designed to enhance the delivery of FDA approved chemotherapeutic agents and reduce their toxicity. To learn more about Sigyn Therapeutics, visit: www.SigynTherapeutics.com
1. Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resist 2019;2:141-60. http://dx.doi.org/10.20517/cdr.2019.10 2. Stanislav Filip, Ondřej Kubeček, Jiří Špaček, Jiřina Martínková, Milan Bláha, Extracorporeal apheresis system – A nanoparticle drugs’ elimination method to enhance the benefit of cytostatic therapy in cancer patients, Journal of Applied Biomedicine, Volume 14, Issue 2, 2016, Pages 91-96, 3. Motamarry, A., Wolfe, A. M., Ramajayam, K. K., Pattanaik, S., Benton, T., Peterson, Y., Faridi, P., Prakash, P., Twombley, K., & Haemmerich, D. (2022). Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities. Cancers, 14(5), 1322. https://doi.org/10.3390/cancers14051322 4. Bandari SK, Purushothaman A, Ramani VC, Brinkley GJ, Chandrashekar DS, Varambally S, et al.. Chemotherapy Induces Secretion of Exosomes Loaded With Heparanase That Degrades Extracellular Matrix and Impacts Tumor and Host Cell Behavior. Matrix Biol (2018) 65:104–18. 10.1016/j.matbio.2017.09.001 5. Keklikoglou, I., Cianciaruso, C., Güç, E. et al. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol 21, 190–202 (2019). https://doi.org/10.1038/s41556-018-0256-3 6. Carson A. Wills, Xiaoming Liu, Longgui Chen, Yuanjun Zhao, Christopher M. Dower, Jeffrey Sundstrom, Hong-Gang Wang; Chemotherapy-Induced Upregulation of Small Extracellular Vesicle-Associated PTX3 Accelerates Breast Cancer Metastasis. Cancer Res 15 January 2021; 81 (2): 452–463. https://doi.org/10.1158/0008-5472.CAN-20-1976 7. Role of extracellular vesicles in chemotherapy-induced lung metastasis Nahal Mansouri, Ioanna Keklikoglou, Sina Nassiri, Bruno Torchia, Alan Guichard, Michele De Palma European Respiratory Journal Sep 2020, 56 (suppl 64) 3944; DOI: 10.1183/13993003.congress-2020.3944 8. Samuel P, Mulcahy LA, Furlong F, McCarthy HO, Brooks SA, Fabbri M, Pink RC, Carter DRF.Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells. Philos Trans R Soc Lond B Biol Sci. 2018 Jan 5;373(1737):20170065. doi: 10.1098/rstb.2017.0065. PMID: 29158318; PMCID: PMC5717443.
Cautionary Note Regarding Forward-Looking Statements
This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Contact: Stephen Kilmer Sigyn Therapeutics, Inc. Investor Relations (646) 274-3580 stephen@sigyntherapeutics.com
Health officials say the strain is worrisome because it may evade prior protections and not respond to current vaccines.
Fresh blood was found on patient’s gown
Prisoner advocacy group calls observation level at Ash Street Jail inadequate; says suicidal suspect Adam Howe should have been sent to Bridgewater.
Parkinson's disease affects around one million people in the United States, according to the Parkinson's Foundation. Beyond that, the number of people who are diagnosed with the disease in the U.S. each year is in the range of 60,000. In fact, following Alzheimer's, it's the most common neurodegenerative disease.A condition that affects a person's nervous system, the exact cause of Parkinson's isn't clear. However, there are things that you can do to try to prevent it. And according to findings
The subvariant has been slowly increasing in prevalence across the U.S., even as the BA.5 subvariant of Omicron remains the dominant strain with 79.2% of the cases. The BA.4.6 subvariant has been found to be better at evading COVID-19 antibody therapies, with the U.S. Food and Drug Administration in early October warning healthcare providers that AstraZeneca's Evusheld had the risk of being ineffective against some variants it cannot neutralize.
Bank of America analysts on Friday told investors that Eli Lilly & Co. Inc.’s (LLY) diabetes treatment and possible weight-management drug could be a $100 billion medication. The drug, tirzepatide, received Food and Drug Administration approval as a treatment for Type 2 diabetes earlier this year. It has also shown in clinical trials that it can help people lose up to 20% of their body weight.
Exhausted nurses and staff triage an often-packed emergency room lobby at all hours, five days in to an outage of the hospital's records system.
Shocker: Keeping 10-15 Skittles or jelly beans nearby can actually be a healthy choice.
Medicare’s annual open enrollment period begins on Oct. 15 and ends on Dec. 7. More than seven in 10 Medicare beneficiaries did not even compare plans during this period in 2018, according to the Kaiser Family Foundation, a nonprofit group focused on health policy. Many times, it’s because making the change — or just reviewing the options — can be overwhelming, said Dave Francis, chief executive officer and co-founder of Healthpilot, a company whose services include automated and personalized Medicare plan recommendations.
Wonder Pill quietly contained a drug used to treat erectile dysfunction, which could be deadly for some unknowing consumers, the FDA said.
Contrary to popular belief, the simple approach to many things in life is often the most effective. An investing quote from Motley Fool contributor Brian Feroldi that I believe is highly underrated goes as follows: "Good investing is 99% patience and 1% action." The pharmaceutical giant Amgen (NASDAQ: AMGN) and medical devices maker Stryker (NYSE: SYK) are two healthcare stocks that appear poised to create wealth for shareholders who are patient and measured enough to let them.
The cuts are intended to reduce costs, streamline operations and increase profitability for BioMarin, frequently tapped as a likely takeover target.
When Sen. Lindsey Graham, R-S.C., proposed a national ban on abortions after 15 weeks of pregnancy, the bill sparked controversy across the political spectrum. But few spoke of its potential impact on the growing number of women who are having children in their 30s. The proposed ban would allow exceptions to save a woman’s life and for some pregnancies resulting from rape and incest, but it notably lacks exceptions for fetal abnormalities. As such, it would sharply restrict options for the growi
If you want to burn fat, should you do cardio or lift weights? Experts weigh in on the benefits of cardio and strength training for weight loss.
For the 1.6 million New Jersey residents who rely on Medicare for their health insurance, make a list of what’s necessary to have in your plan.
A large number of U.S. COVID deaths could be prevented if patients would take Paxlovid, the antiviral developed by Pfizer that helps reduce the risk of hospitalization and death, according to White House COVID coordinator Dr. Ashish Jha.
Commentary: A heartfelt sharing of a mom’s experience.
President Joe Biden has said the pandemic is over, despite more than 300 people dying from COVID-related illness every day. Now cruise lines, which experienced severe disruptions during the early days of the COVID-19 outbreak and, in some cases were stranded offshore due to ports refusing them permission to dock due to coronavirus outbreaks onboard, are relaxing their health protocols. Harry Sommer, chief executive of Norwegian Cruise Line cited “significant, positive progress in the public-health environment.”
Jill Biden on Friday used the story of how one of her teenage friends ended a pregnancy at a time when abortion was illegal, including being declared mentally unfit, to illustrate what she says is at stake for women in November's elections. “How could we go back to that time?” the first lady asked in a political speech to a women's conference sponsored by the House Democrats' campaign arm. Women no longer have a constitutional right to abortion after a conservative majority on the Supreme Court in June overturned its ruling in Roe, allowing individual states to decide whether abortion should be legal.
The health system Kaiser Permanente called doctors in during lunch and after work and urged them to add additional illnesses to the medical records of patients they hadn’t seen in weeks. Doctors who found enough new diagnoses could earn bottles of Champagne or a bonus in their paycheck. Anthem, a large insurer now called Elevance Health, paid more to doctors who said their patients were sicker. And executives at UnitedHealth Group, the country’s largest insurer, told their workers to mine old me